Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)
Lantheus Holdings (LNTH) reported Net Income towards Common Stockholders of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and up 118.93% quarter-over-quarter from $54.1 million in Q4 2025.
Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Net Income towards Common Stockholders data on file, last reported at $118.4 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $118.4 million, up 62.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.0 million (up 9.72% YoY), and the FY2025 annual result was $233.6 million, down 25.25% from the prior year.
- Net Income towards Common Stockholders grew to $118.4 million in Q1 2026 per LNTH's latest filing, from $54.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $132.0 million in Q3 2023 and troughed at -$119.2 million in Q4 2022.
- A 5-year average of $59.9 million and a median of $62.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders plunged 196.37% in 2022, then jumped 4769.26% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$119.2 million in 2022, then surged by 186.74% to $103.4 million in 2023, then slumped by 111.4% to -$11.8 million in 2024, then soared by 558.76% to $54.1 million in 2025, then soared by 118.93% to $118.4 million in 2026.
- Business Quant data shows LNTH's Net Income towards Common Stockholders at $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 54.09 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -11.79 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 103.38 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |
| Jun 30, 2021 | -26.66 Mn |